

Abstract

5 Pharmaceutical compositions containing as active
compound a substance which inhibits the activity of TGF β
on tumour cells of epithelial origin, for the treatment
of epithelial, invasive tumour diseases which are
characterised by a reversible transition of the cells
10 from an epithelial, non-invasive state into a
fibroblastoid, invasive state. The pharmaceutical
composition contains a TGF β inhibitor, preferably
combined with an Ras inhibitor. Process for screening
substances for the treatment of epithelial, invasive
15 tumour diseases.